Guosheng Capital
国生资本
elsewhere's corpus does not cover Guosheng Capital as a subject in its own right. The fund appears only in passing as a continuing investor in Zenitar's Series C round in January 2026, alongside 5Y Capital, Huajin Capital, and Sichuan Sci-Tech Innovation Investment Group . No founding date, size, strategy, or team details are provided in the retrieved material.
AI-generated — may contain errors, please verify.
Guosheng CapitalFund
国生资本
渲染中…
Mentioned in 3 articles
Coverage
New Forces Keep Coming｜5Y News Monthly
The big news from last month.
BlueRun Ventures-backed Zenitar closes nearly RMB 600 million Series C round | BlueRun Family
Build a closed-loop, iterative system spanning "target identification — molecular design — efficacy validation"
5Y News | Zai Ling Bio Completes Nearly RMB 600 Million Series C Financing
The funding will go toward global clinical development, pipeline expansion, and technology platform upgrades.
